Publication

As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.

J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race

The invisible heart disease crisis: Why congenital heart disease is moving up the global health agenda

The ASCO Drug Race Still Runs Through Genomic Testing

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

Alzheimer’s Blood Testing Moves the Disease Clock Earlier

Physical activity continues to strengthen its case as a cross-disease prevention strategy

Can cortisol become the next target in type 2 diabetes?

The Air We Breathe May Be Shaping the Future Burden of Blindness
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
